These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 27304831)

  • 41. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial.
    Worsley R; Jane F; Robinson PJ; Bell RJ; Davis SR
    Climacteric; 2015 Apr; 18(2):270-7. PubMed ID: 25333776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of metformin on simple obesity: a meta-analysis.
    Ning HH; Le J; Wang Q; Young CA; Deng B; Gao PX; Zhang HQ; Qin SL
    Endocrine; 2018 Dec; 62(3):528-534. PubMed ID: 30151735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
    Hasnain M; Fredrickson SK; Vieweg WV
    J Psychopharmacol; 2011 Jun; 25(6):715-21. PubMed ID: 21169390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.
    Ehret M; Goethe J; Lanosa M; Coleman CI
    J Clin Psychiatry; 2010 Oct; 71(10):1286-92. PubMed ID: 20441727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of metformin to control clozapine-associated weight gain in an adolescent with schizoaffective disorder.
    Weaver LA; De León DD; Borgmann-Winter K; Coffey BJ
    J Child Adolesc Psychopharmacol; 2010 Apr; 20(2):153-7. PubMed ID: 20415612
    [No Abstract]   [Full Text] [Related]  

  • 46. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
    Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF
    J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Relationships of Obesity-Related Genetic Variants With Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients With Schizophrenia.
    Chen PY; Lu ML; Huang MC; Kao CF; Kuo PH; Chiu CC; Lin SK; Chen CH
    J Clin Psychopharmacol; 2015 Oct; 35(5):574-8. PubMed ID: 26263223
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of metformin for weight management in patients without type 2 diabetes.
    Desilets AR; Dhakal-Karki S; Dunican KC
    Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.
    Maayan L; Vakhrusheva J; Correll CU
    Neuropsychopharmacology; 2010 Jun; 35(7):1520-30. PubMed ID: 20336059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study.
    Stogios N; Maksyutynska K; Navagnanavel J; Sanches M; Powell V; Gerretsen P; Graff-Guerrero A; Chintoh AF; Foussias G; Remington G; Hahn MK; Agarwal SM
    Acta Psychiatr Scand; 2022 Sep; 146(3):190-200. PubMed ID: 35726126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.
    Mizuno Y; Suzuki T; Nakagawa A; Yoshida K; Mimura M; Fleischhacker WW; Uchida H
    Schizophr Bull; 2014 Nov; 40(6):1385-403. PubMed ID: 24636967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
    Blonde L; Stenlöf K; Fung A; Xie J; Canovatchel W; Meininger G
    Postgrad Med; 2016 May; 128(4):371-80. PubMed ID: 27002421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin.
    Fernández E; Carrizo E; Fernández V; Connell L; Sandia I; Prieto D; Mogollón J; Valbuena D; Fernández I; de Baptista EA; Baptista T
    Schizophr Res; 2010 Aug; 121(1-3):213-7. PubMed ID: 20591628
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
    Jarskog LF; Hamer RM; Catellier DJ; Stewart DD; Lavange L; Ray N; Golden LH; Lieberman JA; Stroup TS;
    Am J Psychiatry; 2013 Sep; 170(9):1032-40. PubMed ID: 23846733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic.
    Chiliza B; Asmal L; Oosthuizen P; van Niekerk E; Erasmus R; Kidd M; Malhotra A; Emsley R
    Eur Psychiatry; 2015 Feb; 30(2):277-83. PubMed ID: 25577186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improvements in body composition, anthropometric measurements and lipid profile following discontinuation of clozapine.
    Wysokiński A; Sobów T
    Nord J Psychiatry; 2016; 70(2):156-60. PubMed ID: 26140393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
    Underdal MO; Stridsklev S; Oppen IH; Høgetveit K; Andersen MS; Vanky E
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2408-2413. PubMed ID: 29659896
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
    Anagnostou E; Aman MG; Handen BL; Sanders KB; Shui A; Hollway JA; Brian J; Arnold LE; Capano L; Hellings JA; Butter E; Mankad D; Tumuluru R; Kettel J; Newsom CR; Hadjiyannakis S; Peleg N; Odrobina D; McAuliffe-Bellin S; Zakroysky P; Marler S; Wagner A; Wong T; Macklin EA; Veenstra-VanderWeele J
    JAMA Psychiatry; 2016 Sep; 73(9):928-37. PubMed ID: 27556593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
    Arman S; Sadramely MR; Nadi M; Koleini N
    Saudi Med J; 2008 Aug; 29(8):1130-4. PubMed ID: 18690305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.